Skip to Main Content
Try STAT+ TODAY
Trending:
Biotech
STAT+
Health
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

This biotech just bought three failed drugs. Here’s why

  • Kate Sheridan

By Kate Sheridan Feb. 5, 2020

Reprints
Pink brain psychology
Adobe

Biopharma companies don’t usually buy experimental drugs that don’t work.

But that’s exactly what CODA Biotherapeutics has done.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Kate Sheridan

Kate Sheridan

Research Reporter

Kate collects and analyzes documents, data, and other information for biotech, health tech, science, and politics stories.

Tags

FDA pulls Evusheld authorization as coronavirus evolution quashes another…
FDA pulls Evusheld authorization as coronavirus evolution quashes another therapy
Live blog: Tracking the meeting of the FDA advisory…
Live blog: Tracking the meeting of the FDA advisory panel on Covid vaccines
Focused exclusively on life sciences, three top investors set…
Focused exclusively on life sciences, three top investors set out on their own
Warren urges the FTC to scrutinize two pharma mergers…
Warren urges the FTC to scrutinize two pharma mergers over “anti-competitive” practices
Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s…
Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s drug rejection
Pharmalittle: Strange bedfellows lobby for Medicare coverage of obesity…
Pharmalittle: Strange bedfellows lobby for Medicare coverage of obesity drugs; FDA working with WHO to probe…

Recommended Stories